Table 1.
Demographics and baseline characteristics of patients recruited for this study
| |
Total |
Group I |
Group II |
|
|---|---|---|---|---|
| n = 38 | n = 27 | n = 11 | ||
| Male gender, n (%) |
27 (71) |
19 (70) |
8 (73) |
|
| Age, years |
69.4 ± 10.7 |
70.9 ± 11.2 |
65.5 ± 7.9 |
|
| Past history, n (%) |
|
|
|
|
| |
Hypertension |
25 (66) |
19 (70) |
6 (55) |
| |
Diabetes mellitus |
16 (42) |
9 (33) |
7 (64) |
| |
Hyperlipidemia |
7 (18) |
4 (15) |
3 (27) |
| |
Smoking |
8 (21) |
4 (15) |
3 (27) |
| |
Atrial fibrillation |
11 (29) |
11 (41) |
0 (0) |
| |
Ischemic stroke |
11 (29) |
9 (33) |
2 (18) |
| |
Intracerebral hemorrhage |
2 (5) |
1 (4) |
1 (9) |
| |
Subarachnoid hemorrhage |
0 (0) |
0 (0) |
0 (0) |
| Infarct side, n (%) |
|
|
|
|
| |
Right |
20 (53) |
13 (48) |
7 (64) |
| |
Left |
18 (47) |
14 (52) |
4 (36) |
| Baseline NIHSS score, mean |
8.2 ± 7.5 |
10 ± 8.2 |
3.9 ± 2.4 |
|
| Interval from onset to treatment with edaravone and hydrogen, h |
16 ± 18.1 |
14.9 ± 18.7 |
18.8 ± 6.3 |
|
| Duration of treatment with edaravone and hydrogen, d |
10.8 ± 3.4 |
10.7 ± 3.5 |
11.1 ± 3 |
|
| Laboratory data |
|
|
|
|
| |
HbA1C,% |
6.3 ± 1.7 |
6 ± 1.4 |
7 ± 2 |
| |
BG, mg/dl |
145.2 ± 58.2 |
134 ± 48.9 |
171.6 ± 68.8 |
| |
TG, mg/dl |
116.7 ± 61.3 |
121 ± 67.7 |
107.8 ± 43.7 |
| |
TC, mg/dl |
194.3 ± 43.4 |
186.6 ± 38.3 |
217.3 ± 49.4 |
| |
LDL, mg/dl |
114.3 ± 33.7 |
109 ± 25.7 |
126.5 ± 44.7 |
| |
UA, mg/dl |
5.3 ± 1.4 |
5.2 ± 1.4 |
5.6 ± 0.9 |
| |
PT-INR |
1.14 ± 0.3 |
1.2 ± 0.3 |
1.1 ± 0.06 |
| |
APTT, seconds |
30.7 ± 3.9 |
31 ± 4.1 |
30.1 ± 3.2 |
| |
Fibrinogen, mg/dl |
336.7 ± 101.9 |
333.6 ± 107.4 |
349 ± 74.9 |
| Hct (%) | 41.3 ± 6.4 | 40.7 ± 6.7 | 42.8 ± 5.3 | |
BG, blood glucose; TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; UA, uric acid; PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Hct, hematocrit.